Rhythm Pharmaceuticals annonce l’approbation par Santé Canada de IMCIVREE® setmélanotide pour…
<!-- Name:DistributionId Value:8834057 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Browsing Tag
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical…
BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe…
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by…
-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) -- -- EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue Interest Agreement with HealthCare Royalty -- --…
NICE Recommends Rhythm’s ▼IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger…
- IMCIVREE will be funded and available for use within 90 days in the National Health Service - BOSTON, July 18, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company…
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating…
--All evaluable patients (N=11) achieved BMI decrease of more than 5 percent at 16 weeks on setmelanotide therapy-- --17.2 percent mean reduction in BMI at 16 weeks-- --15.8 percent (15.9 kg or 35.1 lb) mean weight reduction achieved at…
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Use in Patients with…
-- IMCIVREE now available for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome -- -- First and only FDA-approved therapy that targets…
Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with…
BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity,…
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced…
Rhythm Pharmaceuticals complète la demande de variation de type II à l’Agence européenne des…
BOSTON, 15 oct. 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq : RYTM), une société biopharmaceutique au stade commercial engagée à transformer les soins des personnes atteintes de maladies génétiques rares de l'obésité, a…
Rhythm Pharmaceuticals schließt die Einreichung des Antrags für die Typ-II-Variation für IMCIVREE ®…
BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), ein biopharmazeutisches Unternehmen im kommerziellen Stadium, das sich der Umgestaltung der Versorgung von Menschen mit seltenen genetischen…